Thinly traded nano cap Genetic Technologies Limited (GENE +94.7%) rockets up on a whopping 333x surge in volume in reaction to the impending U.S. commercial launch of its GeneType for Breast Cancer test designed to assess breast cancer risk in patients at least 35 years old.
It plans to commence a limited release across 20 centers in eight states this quarter followed by full launch in Q2.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.